Authorization of prognostic AI medical devices

Source Domain: www.nature.com

The integration of artificial intelligence (AI) in medical devices is progressively being shaped by research guidelines and methodological advancements, as seen in works by Obermeyer, Emanuel, and Collins.
There is a growing focus on the lifecycle management of AI-enabled medical devices, with frameworks and recommendations provided by the U.S. Food and Drug Administration (FDA) and the European Medical Device Coordination Group.
Important discussions around the regulatory aspects, impacts, and ethical considerations of AI in medical technologies are increasingly prominent, highlighted in articles from Riley, Van Smeden, and Lehmann.
Prognosis research is emphasized in conceptualizing methodologies and their impact on healthcare, explored in “Prognosis Research in Healthcare” edited by Riley and colleagues, and by studies such as those conducted by Mikhael and Senders.
Emerging industry guidelines and FDA draft recommendations are aimed at standardizing the marketing submissions and development processes for AI-powered medical devices, addressing challenges and opportunities in technology innovation.
The intersection of AI with clinical care is gaining momentum, as reported in publications reflecting developments in clinical practices, digital health strategies, and the regulatory landscape.